Heart Failure Reviews最新文献

筛选
英文 中文
Sodium-glucose cotransporter-2 inhibitors in acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. 钠-葡萄糖共转运体-2 抑制剂在急性心肌梗死中的应用:随机对照试验的系统回顾和荟萃分析。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-29 DOI: 10.1007/s10741-024-10457-z
Matheus Coelho Meine, Paula Santo, Fabiana Dolovitsch de Oliveira, Gustavo Lenci Marques, Joaquim Spadoni Barboza
{"title":"Sodium-glucose cotransporter-2 inhibitors in acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.","authors":"Matheus Coelho Meine, Paula Santo, Fabiana Dolovitsch de Oliveira, Gustavo Lenci Marques, Joaquim Spadoni Barboza","doi":"10.1007/s10741-024-10457-z","DOIUrl":"https://doi.org/10.1007/s10741-024-10457-z","url":null,"abstract":"<p><p>We aimed to assess the efficacy and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus placebo, initiated within the hospitalization period, in addition to habitual treatment, for treating adult patients with confirmed acute myocardial infarction (AMI). We also conducted subgroup analysis by diabetes mellitus (DM) status and type of AMI. We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs). The primary outcome was hospitalization for heart failure (HF). The secondary outcomes were all-cause death, cardiovascular death, and serious adverse events (AEs). We pooled risk ratios (RR) with a 95% confidence interval (CI) for binary outcomes. The between-study variance was assessed using tau<sup>2</sup> statistics. We included five RCTs, encompassing 11,211 patients. SGLT2i significantly reduced the risk of hospitalization for HF compared to placebo (RR 0.73; 95% CI [0.61, 0.88]). However, the risk of all-cause death (RR 1.05; 95% CI [0.78, 1.41]) and cardiovascular death (RR 1.04; 95% CI [0.84, 1.29]) was similar between the groups, as well as the risk of serious AEs (RR 1.01; 95% CI [0.90, 1.14]). In the subgroup analysis by DM status and type of AMI, there were no significant subgroup differences for the outcomes of hospitalization for HF and all-cause death. In patients with AMI, treatment with SGLT2i is safe and significantly reduces the risk of hospitalization for HF, but it has no impact on all-cause death and cardiovascular death compared to placebo.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The many faces of SCN5A pathogenic variants: from channelopathy to cardiomyopathy. SCN5A 致病变体的多面性:从通道病到心肌病。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-28 DOI: 10.1007/s10741-024-10459-x
Ioannis Vouloagkas, Andrea Agbariah, Thomas Zegkos, Thomas D Gossios, Georgios Tziomalos, Despoina Parcharidou, Matthaios Didagelos, Vasileios Kamperidis, Antonios Ziakas, Georgios K Efthimiadis
{"title":"The many faces of SCN5A pathogenic variants: from channelopathy to cardiomyopathy.","authors":"Ioannis Vouloagkas, Andrea Agbariah, Thomas Zegkos, Thomas D Gossios, Georgios Tziomalos, Despoina Parcharidou, Matthaios Didagelos, Vasileios Kamperidis, Antonios Ziakas, Georgios K Efthimiadis","doi":"10.1007/s10741-024-10459-x","DOIUrl":"https://doi.org/10.1007/s10741-024-10459-x","url":null,"abstract":"<p><p>The SCN5A gene encodes the alpha subunit of the cardiac sodium channel, which plays a fundamental role in the generation and propagation of the action potential in the heart muscle. During the past years our knowledge concerning the function of the cardiac sodium channel and the diseases caused by mutations of the SCN5A gene has grown. Although initially SCN5A pathogenic variants were mainly associated with channelopathies, increasing recent evidence suggests an association with structural heart disease in the form of heart muscle disease. The pathways leading to a cardiomyopathic phenotype remain unclear and require further elucidation. The aim of the present review is to provide a concise summary regarding the mechanisms through which SCN5A pathogenic variants result in heart disease, focusing in cardiomyopathy, highlighting along the way the complex role of the SCN5A gene at the intersection of cardiac excitability and contraction networks.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changing the paradigm in heart failure: shifting from treatment to prevention. 改变心力衰竭的模式:从治疗转向预防。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-23 DOI: 10.1007/s10741-024-10454-2
Alex J Chang, Yilin Liang, Michael P Girouard, Ankeet S Bhatt, Alexander T Sandhu, Andrew J Sauer, Stephen J Greene, Josephine Harrington, Alan S Go, Andrew P Ambrosy
{"title":"Changing the paradigm in heart failure: shifting from treatment to prevention.","authors":"Alex J Chang, Yilin Liang, Michael P Girouard, Ankeet S Bhatt, Alexander T Sandhu, Andrew J Sauer, Stephen J Greene, Josephine Harrington, Alan S Go, Andrew P Ambrosy","doi":"10.1007/s10741-024-10454-2","DOIUrl":"https://doi.org/10.1007/s10741-024-10454-2","url":null,"abstract":"<p><p>Heart failure (HF) poses a major global health challenge with rising prevalence, significant morbidity and mortality, and substantial associated healthcare costs. With aging of the population and an increasing burden of comorbidities, the complex interplay between cardiovascular, kidney, and metabolic risk factors have been thrust into the spotlight and have broadened the traditional focus from HF treatment to an increased emphasis on prevention. In recognition of the evolving HF landscape, the American Heart Association released the PREVENT models which are comprehensive risk assessment tools that estimate 10- and 30-year risk of incident cardiovascular disease and its subtypes, including atherosclerotic cardiovascular disease (ASCVD) and, for the first time, HF. While it is an accurate risk estimation tool and represents a step forward in improving risk stratification for primary prevention of HF, there remain several limitations and unknowns like model performance across disaggregated racial and ethnic groups, the role of traditional ASCVD vs. HF-specific risk factors, HF prediction among those with known ASCVD, and the use of traditional regression techniques in lieu of potentially more powerful machine learning-based modeling approaches. Furthermore, it remains unclear how to optimize risk estimation in clinical care. The emergence of multiple novel pharmacological therapies that prevent incident HF, including sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP1) receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists (MRAs), highlights the importance of accurate HF risk prediction. To provide HF prevention with these effective but costly therapies, we must understand the optimal strategy in sequencing and combining these therapies and prioritize patients at highest risk. Such implementation requires both accurate risk stratification and a better understanding of how to communicate risk to patients and providers. This state-of-the-art review aims to provide a comprehensive overview of recent trends in HF prevention, including risk assessment, care management strategies, and emerging and novel treatments.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The sympathetic nervous system in heart failure with preserved ejection fraction. 射血分数保留型心力衰竭的交感神经系统。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-23 DOI: 10.1007/s10741-024-10456-0
Joshua W-H Chang, Rohit Ramchandra
{"title":"The sympathetic nervous system in heart failure with preserved ejection fraction.","authors":"Joshua W-H Chang, Rohit Ramchandra","doi":"10.1007/s10741-024-10456-0","DOIUrl":"https://doi.org/10.1007/s10741-024-10456-0","url":null,"abstract":"<p><p>The sympathetic nervous system (SNS) is a major mediator of cardiovascular physiology during exercise in healthy people. However, its role in heart failure with preserved ejection fraction (HFpEF), where exercise intolerance is a cardinal symptom, has remained relatively unexplored. The present review summarizes and critically explores the currently limited data on SNS changes in HFpEF patients with a particular emphasis on caveats of the data and the implications for its subsequent interpretation. While direct measurements of SNS activity in HFpEF patients is scarce, modest increases in resting levels of muscle sympathetic nerve activity are apparent, although this may be due to the co-morbidities associated with the syndrome rather than HFpEF per se. In addition, despite some evidence for dysfunctional sympathetic signaling in the heart, there is no clear evidence for elevated cardiac sympathetic nerve activity. The lack of a compelling prognostic benefit with use of β-blockers in HFpEF patients also suggests a lack of sympathetic hyperactivity to the heart. Similarly, while renal and splanchnic denervation studies have been performed in HFpEF patients, there is no concrete evidence that the sympathetic nerves innervating these organs exhibit heightened activity. Taken together, the totality of data suggests limited evidence for elevated sympathetic nerve activity in HFpEF and that any SNS perturbations that do occur are not universal to all HFpEF patients. Finally, how the SNS responds during exertion in HFpEF patients remains unknown and requires urgent investigation.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninvasive biometric monitoring technologies for patients with heart failure. 针对心力衰竭患者的无创生物识别监测技术。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-22 DOI: 10.1007/s10741-024-10441-7
Jose Arriola-Montenegro, Pornthira Mutirangura, Hassan Akram, Adamantios Tsangaris, Despoina Koukousaki, Michael Tschida, Joel Money, Marinos Kosmopoulos, Mikako Harata, Andrew Hughes, Andras Toth, Tamas Alexy
{"title":"Noninvasive biometric monitoring technologies for patients with heart failure.","authors":"Jose Arriola-Montenegro, Pornthira Mutirangura, Hassan Akram, Adamantios Tsangaris, Despoina Koukousaki, Michael Tschida, Joel Money, Marinos Kosmopoulos, Mikako Harata, Andrew Hughes, Andras Toth, Tamas Alexy","doi":"10.1007/s10741-024-10441-7","DOIUrl":"https://doi.org/10.1007/s10741-024-10441-7","url":null,"abstract":"<p><p>Heart failure remains one of the leading causes of mortality and hospitalizations in the US that not only impacts quality of life but also poses a significant public health burden. The majority of affected patients are admitted with signs and symptoms of congestion. Despite the initial enthusiasm, traditional remote monitoring strategies focusing primarily on weight gain failed to improve clinical outcomes. Implantable pulmonary artery pressure sensors provide earlier and actionable data, but most patients would favor forgoing an invasive procedure in favor of an alternative, non-invasive monitoring platform. Several devices utilizing different combinations of multiparameter monitoring to reliably detect congestion have recently been developed and are undergoing testing in the clinical setting. Combining these sensors with the power of artificial intelligence and machine learning has the potential to revolutionize remote patient monitoring and early congestion detection and to facilitate timely interventions by the care team to prevent hospitalization. This manuscript provides an objective review of novel, noninvasive, multiparameter remote monitoring platforms that may be tailored to individual heart failure phenotypes, aiming to improve quality of life and survival.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dietary sodium intake restriction in patients with heart failure: an overview of systematic reviews. 心力衰竭患者的饮食钠摄入限制:系统综述。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-19 DOI: 10.1007/s10741-024-10452-4
Congying Liu, Yating Wang, Heli Zhang, Sumei Tong
{"title":"Dietary sodium intake restriction in patients with heart failure: an overview of systematic reviews.","authors":"Congying Liu, Yating Wang, Heli Zhang, Sumei Tong","doi":"10.1007/s10741-024-10452-4","DOIUrl":"https://doi.org/10.1007/s10741-024-10452-4","url":null,"abstract":"<p><p>This study aimed to identify, assess, and summarize systematic reviews on dietary sodium intake restrictions for patients with heart failure. Literature searches were conducted on Pubmed, CINAHL, ScienceDirect, Cochrane Library, China National Knowledge Infrastructure, and the Wanfang Database up to January 2024. The methodological quality of the included reviews was assessed using the quality assessment tool from the Australian JBI Center for Evidence-Based Healthcare (2016). The results of systematic reviews and meta-analyses were synthesized and presented according to different outcome indicators. Nine systematic reviews were included in this study. The current evidence does not support the fact that dietary sodium intake restrictions for patients with heart failure have a positive impact on mortality rates, rehospitalization rates, and quality of life. Conversely, strict dietary sodium intake restrictions (≤ 2000 mg/day) may increase the risk of death, rehospitalization, and symptom exacerbation. Dietary sodium intake restriction may not have a positive impact on clinical outcomes in patients with heart failure. Nevertheless, more evidence is required to explore the differences in the impact of various levels of dietary sodium restriction on the outcomes and symptom management indicators of patients with heart failure.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction. GLP-1受体激动剂是有希望治疗射血分数保留型心力衰竭的抗炎药物。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-19 DOI: 10.1007/s10741-024-10450-6
Giovanni Battista Bonfioli, Luca Rodella, Marco Metra, Enrico Vizzardi
{"title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction.","authors":"Giovanni Battista Bonfioli, Luca Rodella, Marco Metra, Enrico Vizzardi","doi":"10.1007/s10741-024-10450-6","DOIUrl":"https://doi.org/10.1007/s10741-024-10450-6","url":null,"abstract":"<p><p>Heart Failure with Preserved Ejection Fraction (HFpEF) represents a significant challenge in modern cardiovascular medicine, characterized by diastolic dysfunction and a chronic pro-inflammatory milieu. The high prevalence of comorbidities such as diabetes, visceral obesity, and aging, which contribute to systemic inflammation, plays a pivotal role in the pathogenesis and progression of HFpEF. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), a class of glucose-lowering drugs, have demonstrated a wide range of pleiotropic effects that extend beyond glycaemic control. These effects include the reduction of inflammation and oxidative stress, vasodilation, decreased arterial stiffness, and a reduction in myocardial fibrosis-key factors in the pathophysiology of HFpEF. Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF. These trials also demonstrated a significant reduction in C-Reactive Protein (CRP) levels, reinforcing the hypothesis that suppressing the pro-inflammatory state may yield substantial clinical benefits in this patient population. These findings suggest that GLP-1 RAs could play a crucial role in the management of HFpEF, particularly in patients with obesity, by targeting the underlying inflammatory processes and contributing to better overall cardiovascular outcomes.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart failure with reduced ejection fraction and chronic kidney disease: a focus on therapies and interventions. 射血分数降低型心力衰竭与慢性肾脏病:重点关注疗法和干预措施。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-18 DOI: 10.1007/s10741-024-10453-3
Hesham Salah Eldin Taha, Mohamed Momtaz, Ahmed Adel Elamragy, Omar Younis, Mera Alfred Sabet Fahim
{"title":"Heart failure with reduced ejection fraction and chronic kidney disease: a focus on therapies and interventions.","authors":"Hesham Salah Eldin Taha, Mohamed Momtaz, Ahmed Adel Elamragy, Omar Younis, Mera Alfred Sabet Fahim","doi":"10.1007/s10741-024-10453-3","DOIUrl":"https://doi.org/10.1007/s10741-024-10453-3","url":null,"abstract":"<p><p>In heart failure with reduced ejection fraction (HFrEF), the presence of concomitant chronic kidney disease (CKD) predicts poorer cardiovascular outcomes, more aggravated heart failure (HF) status, and higher mortality. Physicians might be reluctant to initiate life-saving anti-HF medications out of fear of worsening renal function and a higher incidence of adverse events. Moreover, international guidelines do not give clear recommendations on managing this subgroup of patients as well as advanced CKD was always an exclusion criterion in most major HF trials. Nevertheless, in this review, we will highlight several recent clinical trials and post-hoc analyses of major trials that showed the safety and efficacy of the different therapies in HFrEF patients with CKD, besides several small-scale cohorts that tested guideline-directed medical therapies in End Stage Kidney Disease (ESKD). Regarding interventions in this subgroup of patients, we will provide up-to-date data on implantable cardioverter defibrillators, cardiac resynchronization therapy, and coronary revascularization, in addition to mitral valve transcatheter edge-to-edge repair and implantable pulmonary artery pressure sensors.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects. 矿物皮质激素受体拮抗剂与射血分数保留型心力衰竭:当前认识与未来展望。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-17 DOI: 10.1007/s10741-024-10455-1
Xi Chen, Meinv Huang, Yi Chen, Haishan Xu, Meifang Wu
{"title":"Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects.","authors":"Xi Chen, Meinv Huang, Yi Chen, Haishan Xu, Meifang Wu","doi":"10.1007/s10741-024-10455-1","DOIUrl":"10.1007/s10741-024-10455-1","url":null,"abstract":"<p><p>The mineralocorticoid receptor (MR), part of the steroid hormone receptor subfamily within nuclear hormone receptors, is found in the kidney and various non-epithelial tissues, including the heart and blood vessels. When improperly activated, it can contribute to heart failure processes such as cardiac hypertrophy, fibrosis, stiffening of arteries, inflammation, and oxidative stress. MR antagonists (MRAs) have shown clear clinical benefits in patients with heart failure with reduced ejection fraction (HFrEF). However, in cases of heart failure with preserved ejection fraction (HFpEF), there is considerable diversity due to its complex underlying mechanisms, resulting in conflicting findings regarding the effectiveness of MRAs in relevant studies. The concept of phenomapping presents an encouraging avenue for investigating different intervention targets and novel therapies for HFpEF. Post hoc analysis of the TOPCAT trial identified certain HFpEF phenotypes that responded favorably to spironolactone. Growing clinical and preclinical evidence suggests that non-steroidal MRAs, which exhibit greater receptor selectivity, stronger anti-fibrotic and anti-inflammatory properties, and fewer hormone-related side effects, may emerge as another promising treatment option for HFpEF alongside sodium-glucose co-transporter 2 (SGLT2) inhibitors. This review aims to outline the structural and functional characteristics of MR, discuss the physiological effects of its activation and inhibition, and delve into the potential for personalized MRA therapy based on the concept of HFpEF phenotype.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure. 急性心力衰竭患者在院内开始使用钠-葡萄糖协同转运体-2 抑制剂。
IF 4.5 2区 医学
Heart Failure Reviews Pub Date : 2024-10-15 DOI: 10.1007/s10741-024-10446-2
Muhammad Sameer Arshad, Adeena Jamil, Stephen J Greene, Harriette G C Van Spall, Gregg C Fonarow, Javed Butler, Muhammad Shahzeb Khan
{"title":"In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure.","authors":"Muhammad Sameer Arshad, Adeena Jamil, Stephen J Greene, Harriette G C Van Spall, Gregg C Fonarow, Javed Butler, Muhammad Shahzeb Khan","doi":"10.1007/s10741-024-10446-2","DOIUrl":"https://doi.org/10.1007/s10741-024-10446-2","url":null,"abstract":"<p><p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular and kidney benefits to patients with heart failure (HF) and/or chronic kidney disease (CKD), regardless of diabetes status and left ventricular ejection fraction (LVEF). Despite robust data demonstrating the efficacy of SGLT-2 inhibitors in both ambulatory and hospital settings, real-world evidence suggests slow and varied adoption of SGLT2 inhibitors among patients hospitalized for HF. Barriers to implementation of SGLT2i may include clinicians' concerns regarding potential adverse events such as diabetic ketoacidosis (DKA), volume depletion, and symptomatic hypoglycemia; or concerns regarding physiologically expected reductions in eGFR. Guidelines lack specific, practical safety data and definitive recommendations regarding in-hospital initiation and continuation of SGLT2i in patients hospitalized with HF. In this review, we discuss the safety of in-hospital SGLT2 inhibitor initiation based on recent trials and highlight the clinical implications of their early use in patients hospitalized for HF.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信